Login
$CBIO
$13.50 -$0.65 (4.59%) Live

Company Executives

Officer Age In this role Source
Joshua Brumm Also a director
Chief Executive Officer and Director
48 Not stated
Richard Scalzo
Chief Financial Officer
40 Since 2025
1 year
Jonathan McNeill
Chief Operating Officer and President
41 Since 2025
1 year
Ellie Im
Chief Medical Officer
48 Since 2025
1 year
Jan Pinkas
Chief Scientific Officer
57 Since 2025
1 year
Barbara Bispham Hale
General Counsel and Corporate Secretary
40 Since 2025
1 year
Ryan Lynch
See Remarks
Title from the Form 4 dated Sep 16, 2026
42 Not stated
Barbara Harlin Bispham
See Remarks
Title from the Form 4 dated Sep 16, 2026
Not stated Not stated

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
6
serving now
Independent
4 of 6
stated in the proxy
Average tenure
1.7 years
from year joined
CEO also chairs the board
No
Peter Harwin
Director Age On board Independent Committees Other public boards Pay Source
Peter Harwin
40 2024
2 years
Independent None stated Cogent Biosciences, Inc., Apogee Therapeutics, Inc., Damora Therapeutics, Inc., Oruka Therapeutics, Inc., Spyre Therapeutics, Inc. $151,575
Joshua Brumm
48 2025
1 year
Not independent None stated None stated Paid as CEO
Susan Moran
56 2024
2 years
Independent
Audit Committee
Tyra Biosciences, Inc., BioAtla, Inc. Not stated
Jonathan Violin
50 2024
2 years
Not independent
Nominating and Corporate Governance Committee
Dianthus Therapeutics, Inc. Not stated
Alexandra Balcom
42 2024
2 years
Independent
Audit Committee · Chair
None stated $140,466
David Lubner
62 2025
1 year
Independent None stated Arcellx Inc., Dyne Therapeutics, Inc. $294,991

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 21, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support